BioSpace News Archive

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2021 on Thursday, May 13, 2021.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, provided a corporate and financial update for the first quarter ended March 31, 2021.

Antares Pharma, Inc., a specialty pharmaceutical company, reported financial and operating results for the quarter ended March 31, 2021 with record first quarter revenue of $42.1 million and net income of $3.8 million, or $0.02 per basic and diluted earnings per share.

Data from a subset of Group 4 patients available for analysis at 24 months also provide preliminary evidence of continued durable responses and continue to demonstrate a favorable safety profile

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2021.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Benzinga Global Small Cap Conference as follows:

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic chimeric antigen receptor (CAR) T-cells in the field of immuno-oncology, today announced its results for the three-month period ending March 31, 2021.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported first quarter 2021 financial results and provided a business update.